Drugs / MG1102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01809912 | Nov 2010 → Mar 2013 | cancer | Green Cross Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG1102 | “28 day course of intravenous (IV) MG1102 in patients with solid tumors for which no standard therapy is available.” NCT01809912 ↗ |
| Known as | Recombinant human apolipoprotein(a) Kringle V | “Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0.” NCT01809912 ↗ |
| Modality | Protein / enzyme biologic | “MG1102 (Recombinant human apolipoprotein(a) Kringle V )” NCT01809912 ↗ |
| Route | Intravenous | “by IV administration on Day 0” NCT01809912 ↗ |